...
bdtx-img

Black Diamond Therapeutics Inc, Common Stock

BDTX

NSQ

$2.41

+$0.06

(2.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$132.97M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
494.91K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.52
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.31 L
$7.66 H
$2.41

About Black Diamond Therapeutics Inc, Common Stock

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBDTXSectorS&P500
1-Week Return-9.06%-2.12%0.77%
1-Month Return-26.75%-2.54%2.65%
3-Month Return-55.37%-6.28%12.3%
6-Month Return-48.17%-1.36%13.48%
1-Year Return1.69%9.29%33.47%
3-Year Return-59.01%10.05%32.22%
5-Year Return-93.9%43.69%92.85%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue47.00K600.00K2.22M3.24M437.00K[{"date":"2019-12-31","value":1.45,"profit":true},{"date":"2020-12-31","value":18.53,"profit":true},{"date":"2021-12-31","value":68.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.5,"profit":true}]
Gross Profit(47.00K)(600.00K)(2.22M)(3.24M)(437.00K)[{"date":"2019-12-31","value":-4700000,"profit":false},{"date":"2020-12-31","value":-60000000,"profit":false},{"date":"2021-12-31","value":-221700000,"profit":false},{"date":"2022-12-31","value":-323800000,"profit":false},{"date":"2023-12-31","value":-43700000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses29.33M69.57M126.87M92.83M86.46M[{"date":"2019-12-31","value":23.12,"profit":true},{"date":"2020-12-31","value":54.83,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.17,"profit":true},{"date":"2023-12-31","value":68.15,"profit":true}]
Operating Income(8.90M)(69.57M)(126.87M)(92.83M)(86.46M)[{"date":"2019-12-31","value":-890400000,"profit":false},{"date":"2020-12-31","value":-6957000000,"profit":false},{"date":"2021-12-31","value":-12687200000,"profit":false},{"date":"2022-12-31","value":-9282800000,"profit":false},{"date":"2023-12-31","value":-8646000000,"profit":false}]
Total Non-Operating Income/Expense(25.89M)6.36M4.74M3.69M5.94M[{"date":"2019-12-31","value":-407.38,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":74.58,"profit":true},{"date":"2022-12-31","value":58.06,"profit":true},{"date":"2023-12-31","value":93.49,"profit":true}]
Pre-Tax Income(35.26M)(67.25M)(125.60M)(88.92M)(82.44M)[{"date":"2019-12-31","value":-3525800000,"profit":false},{"date":"2020-12-31","value":-6725400000,"profit":false},{"date":"2021-12-31","value":-12559600000,"profit":false},{"date":"2022-12-31","value":-8891900000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false}]
Income Taxes5.88M(1.77M)(2.39M)(4.40M)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-30.16,"profit":false},{"date":"2021-12-31","value":-40.66,"profit":false},{"date":"2022-12-31","value":-74.75,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(41.14M)(65.48M)(123.20M)(84.52M)-[{"date":"2019-12-31","value":-4114300000,"profit":false},{"date":"2020-12-31","value":-6547900000,"profit":false},{"date":"2021-12-31","value":-12320300000,"profit":false},{"date":"2022-12-31","value":-8452000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(35.26M)(67.25M)(125.60M)(91.17M)(82.44M)[{"date":"2019-12-31","value":-3525800000,"profit":false},{"date":"2020-12-31","value":-6725400000,"profit":false},{"date":"2021-12-31","value":-12559600000,"profit":false},{"date":"2022-12-31","value":-9116900000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(41.14M)(65.48M)(123.20M)(84.52M)(82.44M)[{"date":"2019-12-31","value":-4114300000,"profit":false},{"date":"2020-12-31","value":-6547900000,"profit":false},{"date":"2021-12-31","value":-12320300000,"profit":false},{"date":"2022-12-31","value":-8452000000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false}]
EPS (Diluted)(4.74)(2.05)(3.47)(2.52)(1.88)[{"date":"2019-12-31","value":-474,"profit":false},{"date":"2020-12-31","value":-205,"profit":false},{"date":"2021-12-31","value":-347,"profit":false},{"date":"2022-12-31","value":-252,"profit":false},{"date":"2023-12-31","value":-188,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BDTX
Cash Ratio 5.42
Current Ratio 5.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BDTX
ROA (LTM) -32.78%
ROE (LTM) -63.09%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BDTX
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BDTX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.40
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Black Diamond Therapeutics Inc share price today?

Black Diamond Therapeutics Inc (BDTX) share price today is $2.41

Can Indians buy Black Diamond Therapeutics Inc shares?

Yes, Indians can buy shares of Black Diamond Therapeutics Inc (BDTX) on Vested. To buy Black Diamond Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BDTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Black Diamond Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Black Diamond Therapeutics Inc (BDTX) via the Vested app. You can start investing in Black Diamond Therapeutics Inc (BDTX) with a minimum investment of $1.

How to invest in Black Diamond Therapeutics Inc shares from India?

You can invest in shares of Black Diamond Therapeutics Inc (BDTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in BDTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Black Diamond Therapeutics Inc shares
What is Black Diamond Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Black Diamond Therapeutics Inc (BDTX) is $7.66. The 52-week low price of Black Diamond Therapeutics Inc (BDTX) is $2.31.

What is Black Diamond Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Black Diamond Therapeutics Inc (BDTX) is

What is Black Diamond Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Black Diamond Therapeutics Inc (BDTX) is 1.40

What is Black Diamond Therapeutics Inc dividend yield?

The dividend yield of Black Diamond Therapeutics Inc (BDTX) is 0.00%

What is the Market Cap of Black Diamond Therapeutics Inc?

The market capitalization of Black Diamond Therapeutics Inc (BDTX) is $132.97M

What is Black Diamond Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Black Diamond Therapeutics Inc is BDTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top